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Background: Inflammation is a common feature in the majority of cardiovascular disease, including Diabetes
Mellitus (DM). Levels of pro-inflammatory markers have been found in increasing levels in serum from diabetic
patients (DP). Moreover, levels of Cyclooxygenase-2 (COX-2) are increased in coronary arteries from DP.
Methods: Through a cross-sectional design, patients who underwent CABG were recruited. Vascular smooth muscle
cells (VSMC) were cultured and COX-2 was measured by western blot. Biochemical and clinical data were collected from
the medical record and by blood testing. COX-2 expression was analyzed in internal mammary artery cross-sections by
confocal microscopy. Eventually, PGI2 and PGE2 were assessed from VSMC conditioned media by ELISA.
Results: Only a high glucose concentration, but a physiological concentration of triglycerides exposure of cultured
human VSMC derived from non-diabetic patients increased COX-2 expression .Diabetic patients showed increasing
serum levels of glucose, Hb1ac and triglycerides. The bivariate analysis of the variables showed that triglycerides was
positively correlated with the expression of COX-2 in internal mammary arteries from patients (r2 = 0.214, P < 0.04).
Conclusions: We conclude that is not the glucose blood levels but the triglicerydes leves what increases the
expression of COX-2 in arteries from DP.
Keywords: Human arteries, Lipid profile, COX-2, Diabetes mellitusIntroduction
Over the past two decades increases in obesity, due to
high caloric intakes and immobilizing technologies, has
led to a surge in type 2 diabetes. In obesity elevated cir-
culating fatty acids set-off a pro-inflammatory cascade, a
common feature with diabetes mellitus. Epidemiological
studies show that the prevalence of Diabetes Mellitus
(DM) has increased worldwide in the last few years [1,2].
Diabetes Mellitus confers a 2- to 4-fold increase in car-
diovascular risk compared with the general population
[3]. Type 2 DM usually coexists with other risk factors
such as hypertension and hyperlipidemia. This scenario* Correspondence: santiredondo@hotmail.com
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distribution, and reproduction in any mediumleads to vascular complications which are the main
cause of morbidity and mortality in these patients. Along
with increasing levels of blood glucose, diabetic patients
also exhibit dyslipemia. Dyslipemia characteristically
consists of decreased levels of high-density lipoproteins
(HDL) cholesterol, elevated levels of low-density lipopro-
tein (LDL) cholesterol and elevated levels of triglycerides
(TG) [4-6]. Regarding the risk factors responsible for the
evolution of atherosclerosis in diabetic patients, Bierman
[7] estimated that typical risk factors including smoking,
cholesterol and blood pressure can account for no more
that 25-30% of excess cardiovascular risk factor in dia-
betic patients. This suggests that other factors might play
a key role in the progression of atherosclerosis in diabetes.
In this context, cardiovascular disease and diabetes are
both associated with elevated levels of inflammatoryed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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(CRP) [8]. Another inflammatory protein involved in
atherosclerosis is cyclooxygenase-2. Cyclooxygenases-1
and −2 (COX-1 and COX-2), which are the key en-
zymes in prostaglandin biosynthesis, are thought to be
important in maintaining the normal physiological
function and certain pathological processes. The indu-
cible form of COX, named COX-2, is not expressed
under physiological conditions but it can be rapidly
expressed under certain circumstances [9]. COX-2 is a
rate-limiting enzyme that catalyzes the conversion of
free arachidonic acid into prostaglandin H2, the first
step in the biosynthesis of prostaglandin and thromb-
oxane. A recent paper has shown that COX-2 is highly
expressed in vascular smooth muscle cells (VSMC) in
a type 2 diabetic mouse model [10] and in coronary arteries
from diabetic patients [11]. Moreover, results from our
group show that COX-2 expression is higher in internal
mammary arteries from diabetic patients and this is closely
related to increased expression of the antiapoptotic protein
Bcl-2 [12]. This mediates an increased proliferation/
apoptosis ratio in VSMC from diabetic patients and a
subsequent pathologic vascular remodeling [13].
This enzyme might be responsible, at least in part, for
some of the changes in vascular reactivity that occur in
arteries from diabetic patients [11]. Although high glu-
cose conditions have been involved in the expression of
COX-2 in VSMC in vitro [14] there is no further infor-
mation about which serum component, if any, might
trigger the differential expression of COX-2 in arteries
from diabetic patients. Therefore, we aim to determine
which serum biomarkers could explain the elevation in
COX-2 expression in arteries from type 2 diabeticFigure 1 Flow diagram of the patients. Patients were recruited as statedpatients. Identification of such serological markers may
reveal new approaches to the prevention of cardiovascu-
lar complications in diabetic and pre-diabetic patients.Results
Characteristics of the patients
A group of 116 atherosclerotic patients were recruited
from those undergoing CABG in the Service of Cardiac
Surgery (Hospital Clínico San Carlos, Madrid). A flow dia-
gram of the patients is shown in Figure 1.
Of these patients, 15% were women and 33% smokers
and the age was 64.7±+9 years old (ranged from 37 to 80
years old). The patients shared the classical comorbidities
such as hypertension (58% of the patients), hyperlipidemia
(59% of the patients) and Diabetes Mellitus (44%) as shown
in Table 1. In terms of biochemical characteristics, glucose
and percentage of Hb1ac were higher in diabetic patients
(DP) compared with non-diabetic patients (non-DP). We
also found that triglycerides were elevated in DP whereas
LDL was lower (Table 2).Expression of COX-2 in VSMC induced by glucose or
triglycerides
We analyzed in vitro whether increasing concentrations of
glucose or triglycerides induced the expression of COX-2.
Since basal expression of COX-2 in cells from DP was
already high, we used VSMCV from non-diabetic subjects.
Human VSMC from non diabetic patients treated with in-
creasing concentrations of glucose (5-25 mM) showed
COX-2 expression was very slightly increased with the
highest concentration of glucose used (25 mM) (Figure 2,
Panel A). On the other hand, treatment of VSMC fromin Methods.
Table 1 Clinical characteristics of the patients studied
Variable Complete group Non- diabetic Diabetic P
Number of patients 116 65 51 -
Age (years) 64.7 ± 9 63.4 ± 9.5 66.4 ± 8.2 0.07 *
Women (%) 17 (15%) 8 (12%) 9 (18%) 0.42 †
Body Mass Index 27.3 ± 3.4 27 ± 3.2 27.6 ± 3.7 0.37 *
Smoking 38 (33%) 25 (38%) 13 (25%) 0.13 †
Hypertensives 64 (55%) 18 (35%) 33 (56%) 0.06 †
Hyperlipidemics 69 (59%) 37 (57%) 32 (63%) 0.53 †
Previous AMI (<30days) 20 (17%) 14 (21%) 6 (12%) 0.17 †
Previous AMI (31–90 days) 9 (8%) 2 (4%) 6 (12%) 0.13 ‡
Previous AMI (>90days) 37 (32%) 16 (25%) 21 (41%) 0.05 †
BMI = body mass index. AMI = acute myocardial infarction. * = Student T-test, † = Chi-squared, ‡ = Fisher test.
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triglycerides (100-250 mg/dL) showed a marked increase
in the expression of COX-2 as shown in Figure 2, Panel B.
Relationship between serum parameters and COX-2
expression in patients
Some authors have shown that the expression of COX-2
in VSMC in culture was induced by high levels of glu-
cose [14]. However, it is not clear whether serum levels
of glucose are related with the levels of COX-2 expres-
sion. We studied the vascular expression of the inflam-
matory protein COX-2 in cross-sections of internal
mammary arteries from DP and non-DP analyzed by
confocal microscopy and analyzed the correlationTable 2 Biochemical characteristics of the patients studied
Variable Complete group
Glucose (mg/dL) ¶ 110 ± 44
Hb1ac (%)
¶ 6.4 ± 1.2
Total cholesterol (mg/dL) ¶ 154 ± 47
HDL-cholesterol (mg/dL) ¶ 41 ± 12
LDL-cholesterol (mg/dL) ¶ 82 ± 37
non-HDL cholesterol (mg/dL) ¶ 113 ± 41
Triglycerides (mg/dL) ¶ 137 ± 68
Creatinine (mg/dL) ¶ 1.08 ± 0.2
Creatinine (mg/dL) ¶ 1.08 ± 0.2
Fibrinógen (mg/dL) 453 ± 102
Homocysteine (μmol/L) 11 ± 2.9
Apoprotein A (mg/dL) 116 ± 25.2
C-reactive protein (mg/mL) 3.6 ± 3.8
Interleukin-6 (pg/mL) 9.3 ± 3.1
TNF-α (pg/mL) 6.2 ± 2.2
MMP-9 (ng/mL) 301 ± 300
¶ = ? armonic mean, § = Student T-test, * = Welch test (Beherens-Fisher), ¤ = U test Mbetween serum glucose or Hb1ac and COX-2 expression
in arteries. As shown in Figure 3, there was no statisti-
cally significant correlation between glucose or Hb1ac
and COX-2 expression. However, in terms of the lipid
profile, we found a good correlation between serum
levels of triglycerides and COX-2 expression (Figure 4,
panel A), but not with LDL (Figure 4, panel B), HDL
(Figure 4, panel C) or total colesterol (Figure 4, panel
D). In another set of experiments, we measured the ex-
pression of the antioxidant protein HO-1 in internal
mammary arteries from DP and non-DP by confocal mi-
croscopy. However, a statistically signigicant difference
was not found (2.027 ± 0.2352 vs. 2.140 ± 0.1039 arbitrary
units, p = 0.7173).Non-diabetic Diabetic P
93 ± 19 136 ± 50 < 0.001 *
5.6 ± 0.4 7.4 ± 1.1 < 0.001 *
158 ± 51 148 ± 40 0.221 §
42 ± 14 39 ± 10 0.238 §
89 ± 40 73 ± 32 0.019 §
116 ± 43 116 ± 38 0.230 §
125 ± 42 154 ± 87 0.005 §
1.08 ± 0.2 1.08 ± 0.2 0.530 §
1.08 ± 0.2 1.08 ± 0.2 0.530 §
455 ± 110 451 ± 93 0.841 §
11 ± 1.5 11 ± 2.9 0.499 ¤
118 ± 28.1 114 ± 19.3 0.551 ¤
3.3 ± 3.4 3.6 ± 3.8 0.880¤
9.46 ± 2.8 9.21 ± 3.3 0.750¤
6.3 ± 2.2 6.1 ± 2.1 0.525¤
458 ± 186 260 ± 397 0.103¤
ann–Whitney-Wilcoxon), mad =media absolute deviation.
Figure 2 Expression of COX-2 in human vascular smooth muscle cells. Panel A: effect of glucose. Left panel: Western blotting shows the
expression of COX-2 in non diabetic VSMC incubated with increasing concentrations of glucose. Right panel: Bar graph shows the mean±SEM of
n = 4 patients, *P < 0.05 with respect to 5 mM glucose. Panel B: effect of triglycerides. Left panel: Western blotting shows the expression of COX-2
in non diabetic VSMC incubated with increasing concentrations of triglycerides. Right panel: Bar graph shows the mean±SEM of n = 4 patients,
***P < 0.001 with respect to control (vehicle, glycerol). Panel C: Effects of glyceril palmytate as a pure source of triglycerides.
Figure 3 Bivariate correlation between serum glucose (panel A) or Hb1ac (panel B) and COX-2 expression COX-2 expression was
quantified in the media layer of internal mammary arteries from DP and non-DP by confocal microscopy (n = 34 patients). Analysis was
performed by Pearson correlation.
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Figure 4 Bivariate correlation between the lipid profile and COX-2 expression in internal mammary arteries. COX-2 expression was
quantified in the media layer of internal mammary arteries from DP and non-DP by confocal microscopy (n = 34 patients). Analysis was
performed by Pearson correlation.
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To study the consequences of COX-2 expression, we
determined the production of PGI2 and PGE2 in human
VSMC from DP and non-DP. As shown in Figure 5,
Panel A, the basal release of PGI2 into the cellular
medium was decreased in vascular smooth muscle cells
isolated from diabetic patients compared with non-
diabetic. However, the basal production of PGE2 was
similar in human vascular smooth muscle cells from DP
compared with non-DP (Figure 5, Panel B). On the
other hand, since production of PGE2 has been associ-
ated with increasing levels of MMP-9, we studied the
correlation between COX-2 expression in the vascula-
ture with the serum levels of MMP-9. Figure 5, Panel C
shows that COX-2 expression correlates with the serum
MMP-9 (r2 = 0.657, P = 0.02).
Discussion
In the present work we have found that the inflammatory
enzyme COX-2 was highly expressed in internal mam-
mary arteries from diabetic patients. Moreover, since our
aim was to evaluate which serum biomarker(s) was (were)
responsible for COX-2 expression, we performed a trans-
lational study in which we recruited a group of 116 ath-
erosclerotic patients with or without DM as a risk factor.
Data from this study showed that DP had increasing levelsof glucose and Hb1ac, as expected, but also triglycerides
(TG). From this, we studied the correlation of these
markers with the vascular expression of COX-2 by a bi-
variate analysis and we found that TG levels correlated
with the expression of COX-2.
Some authors have shown previously that high levels of
glucose induced COX-2 expression in several cell types.
High glucose-induced COX-2 expression in monocytes is
regulated by NFk-B, protein kinase-C and p38 MAPK sig-
nalling pathways [15]. Protein kinase-C has also been in-
volved in COX-2 expression in rat vascular smooth
muscle cells in culture [16]. However, a comprehensive
analysis of the intracellular mechanism underlying COX-2
expression in human vascular smooth muscle cells is out
of the scope of this manuscript.
We evaluated in human vascular smooth muscle cells in
culture the effect of different concentrations of glucose in
the cellular medium. We found that glucose 25 mM
slightly but significantly increased the expression of COX-
2 in cells from non-DP. Although sporadically glucose
levels in DP may reach the concentration of 25 mM, the
glucose levels in blood from our diabetic patients were in
a range of 8-10 mM. In fact, the bivariate analysis of glu-
cose (or Hb1ac) versus COX-2 expression showed no cor-
relation, which indicates that the expression of COX-2 in
arteries from DP should be related with other factors.
Figure 5 Consequence of COX-2 expression. Basal release of
prostacyclin (Panel A) or PGE2 (Panel B) in VSMC from DP and non-DP.
Bar graph shows the mean±SEM of n = 4 patients, **P < 0.01. Panel C:
Bivariate correlation between serum MMP-9 levels and COX-2
expression in internal mammary arteries. Analysis was performed by
Pearson correlation.
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could be related to changes in the lipid profile of our pa-
tients. As shown in Figure 3, the levels of triglycerides
positively correlated with the expression of COX-2. This
fact indicates that it is the lipid profile rather than gly-
caemia which might regulate the expression of COX-2 in
diabetic patients. This, along with the fact that levels of tri-
glycerides were higher in diabetic patients, leads to the
conclusion that elevated triglyceride levels in diabetic pa-
tients, but not glucose, is responsible for the
overexpression of COX-2 in arteries from diabetic pa-
tients. To corroborate this, when human VSMC from
non-DP were treated with different concentrations of tri-
glycerides we found that, unlike glucose, treatment with
triglycerides induced COX-2 expression in cells from ND
patients.Dislipemia, associated with high levels of triglycerides
and low concentrations of HDL contributes to a
proinflammatory state [17]. In this context, the adipose
tissue, in addition to storing calories as triglycerides,
also secretes a large variety of pro-inflammatory pro-
teins [18] which contributes to cardiovascular disorders.
The consequences of COX-2 expression in atheroscler-
otic vessels are not fully understood. The induction of
COX-2 in vivo is generally associated with deletereous re-
sponses. However, in the presence of endothelial dysfunc-
tion (i.e. in diabetes) the local induction of COX-2 in the
underlying smooth muscle cells may compensate for the
reduced thrombo-resistance of that section of the vessel
and may also compensate for the decrease in nitric oxide-
dependent vasorelaxation observed in diabetic arteries
[19]. Thus, endogenous PGI2 release as a result of COX-2
expression is considered beneficial in the cardiovascular
system since it decreases VSMC proliferation [20], choles-
terol accumulation and platelet activation and increases
vasodilation [21,22]. Interestingly, PGI2 synthesis from hu-
man aorta samples decreases as a function of progressing
atherosclerotic lesion, whereas PGE2 increases in parallel
[23]. PGE2 is a proatherogenic eicosanoid when released
in advanced atherosclerotic plaques since it may induce
the release of metalloproteinases (MMP) such MMP-2
and MMP-9, enzymes capable of degrading all macromol-
ecular constituents of the extracellular matrix [24] and
thus participate in atherothrombosis. In this work, we
evaluated the release of basal PGI2 and PGE2 in human
VSMC isolated from DP and non-DP. We found that, al-
though the basal levels of PGE2 were similar in both
groups of patients, the release of PGI2 decreased in cells
from diabetic patients. Some postulations may be made
about the surprising fact the fact that PGI2 levels in cells
from diabetic patients was lower than in non-diabetic
ones. One of the most outstanding candidates for PGI2 in-
hibition in the diabetic scenario is the peroxynitrite oxy-
gen reactive form (ONOO-), which has been shown to
perform a selective nitration PGI2 synthase in in vitro
models of diabetes and therefore inhibit PGI2 synthesis
[25]. This increase in ONOO- is thought to take place by
means of eNOS uncoupling in diabetes [26], which may
be related to a decreased eNOS expression in the internal
mammary arteries of diabetic patients who underwent
by-pass surgery. Moreover, the analysis of COX-2 and
MMP-9 indicated a correlation between these proteins.
The latter might indicate that, persistent overexpression of
COX-2 in diabetic patients might lead to a deleterious effect.
According to our results, it is intriguing to systematically
assess plasma and urine levels of eicosanoids such as LTs
and TXs, plasma and RBC membrane levels of antioxi-
dants such as SOD, catalase and glutathione as well as
plasma levels of NO in DP and non-DP undergoing
CABG surgery. This could help to broaden our knowledge
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flammation, eicosanoids, oxidative stress and subsequent
endothelial funcition and will be the goal of coming re-
search efforts.
Conclusions
In conclusion, this work describes for the first time that
vascular inflammation in diabetic patients is determined
by changes in the lipid profile, rather than by glycaemia.
This might have important clinical implications in the way
that diabetic patients need to be treated to prevent




All reagents were obtained from Sigma (Spain) unless
otherwise stated.
Patients
A group of patients was recruited from those undergoing
coronary artery bypass graft surgery at the Cardiac Surgery
Service (Hospital Clinico San Carlos, Madrid, Spain).
Diabetes Mellitus was defined following the criteria
established by the ADA (American Diabetes Association)
[27] as fasting serum glucose concentration ≥126 mg/dl
and use of antidiabetic oral drugs or insulin. Patient data
included: age, gender, active smoker, obesity, total choles-
terol, cholesterol LDL, cholesterol HDL, triglycerides, glu-
cose and blood pressure. Exclusion criteria of the patients
included patients older than 80 years of age, pathologies
that affect the inflammatory status (renal failure, liver dis-
ease, etc.) and cancer. Internal mammary arteries were
collected by the surgeons during the surgical procedure,
labeled and used within the next few minutes after the op-
erations. The study was conducted according to the Dec-
laration of Helsinki and we obtained informed consent
from all subjects before sampling took place. The study
was approved by the local Ethical Committee (Hospital
Clinico San Carlos, Madrid, Spain). From all included
patients we had access to the clinical report and blood
sample. However, for surgical limitations, a proper internal
mammary artery segment for further confocal microscopy
analysis or cell cultures experiments could not be obtained
from all CABG patients. Thus, we performed the experi-
ments under controlled conditions with the maximal num-
ber of samples we could obtain from our clinical group.
Analysis of blood samples
Serum samples were collected from each patient by the
Service of Clinical Analysis (Hospital Clínico San Carlos,
Madrid) before the operations took place. Typical bio-
chemical biomarkers (cholesterol, glucose, triglycerides,
LDL, HDL, etc.) were analyzed in the Service of ClinicalAnalysis. Serum samples for cytokines profile were pre-
pared, frozen and stored at −70°C until the assay. Levels
of C-reactive protein (CRP), interleukin-6 (IL-6) matrix
metalloproteinase-9 (MMP-9), and CD40L were mea-
sured by enzyme-linked immunosorbent assay (ELISA)
(Quantikine, R&D System, Madrid, Spain).
Cell cultures
Human internal mammary artery vascular smooth muscle
cells (VSMC) were cultured from explants in RPMI (Life
Technologies, Barcelona, Spain) containing 10% fetal calf
serum (FCS). The cells exhibited typical “hill and valley”
smooth muscle morphology by phase contrast microscopy
and the cultures were stained positively with a monoclonal
anti-smooth α-actin antibody. Experiments were performed
with VSMC between passages 3 and 5. To determine the
expression of COX-2, cells were plated onto 60 mm tissue
culture dishes and allowed to attach for 24 h. To analyze
the effect of glucose or triglycerides on COX-2 expression,
VSMC from non-diabetic patients were treated for 48h
with 5–25 mM of glucose (or mannitol 25 mM) or with
triglycerides (purified soya oil emulsion Intralipid©,
Fresenius-Kabi, Madrid, Spain) at 100-250 mg/dL for 24 h.
Western blotting
At the time of harvest, the cells were washed with ice-
cold PBS, lysed on ice with 200 μL lysis buffer (10% gly-
cerol, 2.3% SDS, 62.5 mM Tris–HCl, pH 6, 8 150 mM
NaCl, 10 mM EDTA, 1 μg/mL leupeptin, 1 μg/mL
pepstatin, 5 μg/mL chymostatin, 1 μg/mL aprotinin,
1 mM phenylmethylsulphonyl fluoride) and boiled for
5 min. Equal amounts of protein were run on 10% SDS-
polyacrylamide gel electrophoresis. The proteins were
then transferred to polyvinylidene difluoride (PVDF)
membranes (Immobilon-P, Amersham, Madrid, Spain),
and blocked overnight at 4°C in blocking solution (3%
BSA in TBS-T: 25 mM Tris–HCl, 75 mM NaCl, pH =
7.4, 0.1% v/v Tween 20). For analysis of COX-2 expres-
sion, the blots were incubated overnight with agitation
at 4°C in the presence of a specific mouse monoclonal
anti-COX-2 antibody (Transduction Labs., Madrid,
Spain) at 1:1000 in in 0.3% bovine serum albumin in
TBS-T. After washing in TBS-T solution, the blots were
further incubated for 1 h at room temperature with a
horseradish peroxidase conjugated anti-mouse secondary
antibody diluted 1:10,000 (Santa Cruz Biotechnology, CA,
USA) in blocking solution. The blots were then washed 5
times in TBS-T and antibody-bound protein was visualized
with Enhanced Chemiluminescence’s (ECL) kit (Amershan
Biosciences, Barcelona, Spain). Smooth muscle α-actin was
used as a housekeeping protein and it was determined
following the same procedure as mentioned above, using
a specific anti-α-actin mouse monoclonal antibody (Sigma-
Aldrich, Madrid, Spain), at 1:1,000 in TBS-T.
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Small segments of internal mammary arteries were fixed
with 4% paraformaldehyde for 2 h, washed with PBS,
immersed in PBS 0.1 mol/l + sucrose 30% at 4°C for 3 h
and embedded in OCT (OCT-tissue tek, Bayer) for 30 min.
Cross sections 7 μm thick were obtained (Cryostat HM500,
Microm international GMBH, Dusseldorf), dried at 37°C
and washed with PBS + 0.3% Tween-20 (PBS-T). Unspecific
binding was blocked by incubating the samples for 1 h in
3% bovine albumin in PBS-T. Cross sections were incu-
bated with mouse monoclonal anti-COX-2 or anti-HO-1
antibodies at 1:100 (BD Transduction Labs., Madrid, Spain)
for 1 h at 37°C and after washing, with Alexa-568 goat anti-
mouse secondary antibodies (Molecular Probes, USA) at
1:500 for 1 h at 37°C. Confocal microscopy images were by
captured using a Leica TCS SP2 inverted microscope (ob-
jective = 63×, the excitation and emission wave length were
543 and 603 nm respectively). Semiquantitative measure of
COX-2 expression was performed by using the Image J
1.33 software (NIH, USA). Data are presented as fold in-
crease of protein expression with respect to each negative
control. COX-2 expression was quantified in the media
layer of internal mammary arteries from DP and non-DP
by confocal microscopy (n = 34 patients). Analysis of
COX-2 intensity was done by two independent researchers
and the concordance analyzed with the Intraclass Correl-
ation Coefficient. The value obtained was 0.78, within ac-
ceptable range.Analysis of PGE2 and PGI2 production
Release of PGE2 and PGI2 into the culture medium was
determined as an index of COX-2 activity. Vascular
smooth muscle cells from DP and non-DP were plated
on 24-well plates and allowed to attach for 24 h. Cellular
medium was collected and PGE2 and PGI2 concentration
analyzed by enzyme immunoassay (for PGE2; Cayman
Chemical, MI, USA. For PGI2; Quantikine, R&D System,
Madrid, Spain) following the manufacturer’s instruc-
tions. Data were expressed as pg PGE2 or PGI2 per mg
of total protein.Statistical analysis
Data are reported as mean and standard error of the mean
(SEM) for continuous variables. Comparison and correl-
ation analyses were performed with Student T-test and
Pearson coefficient correlation or the correspondent non-
parametric tests. Analysis of variance (ANOVA) was used
to test for differences in means across treatment groups,
and with significant differences a post hoc HSD-Tukey test
was used to compare specific treatment groups. Differ-
ences with a P value of less than 0.05 were considered
statistically significant. Analyses were performed with
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